NCT05525325 Mode of Sedation During Endovascular Treatment of Vertebrobasilar Stroke
| NCT ID | NCT05525325 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital Heidelberg |
| Condition | Stroke Thrombectomy |
| Study Type | INTERVENTIONAL |
| Enrollment | 128 participants |
| Start Date | 2022-10-01 |
| Primary Completion | 2029-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 128 participants in total. It began in 2022-10-01 with a primary completion date of 2029-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Optimal anesthetic mode is not established for patients with vertebrobasilar stroke undergoing endovascular treatment. We want to investigate whether a procedural sedation mode approach is feasible compared to general anesthesia
Eligibility Criteria
Inclusion Criteria: 1. Decision for thrombectomy according to local protocol for acute recanalizing stroke treatment 2. Age 18 years or older, either sex 3. National Institutes of Health Stroke Scale (NIHSS) ≥ 4 4. Acute ischemic stroke in the posterior circulation with isolated or combined occlusion of vertebral artery (VA) and basilar artery (BA) 5. Informed consent by the patient him-/herself or his/her legal representative obtainable within 72 h of treatment (deferred consenting procedure) Exclusion Criteria: 1. Intracerebral hemorrhage 2. Coma on admission (Glasgow Coma Scale ≤ 8) 3. Severe respiratory instability, loss of airway protective reflexes or vomiting on admission, where primary intubation and general anesthesia is deemed necessary 4. Intubated state before randomization 5. Severe hemodynamic instability (e.g. due to decompensated cardiac insufficiency)
Contact & Investigator
Silvia Schönenberger, MD
PRINCIPAL INVESTIGATOR
University Hospital Heidelberg
Frequently Asked Questions
Who can join the NCT05525325 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Stroke Thrombectomy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05525325 currently recruiting?
Yes, NCT05525325 is actively recruiting participants. Contact the research team at min.chen@med.uni-heidelberg.de for enrollment information.
Where is the NCT05525325 trial being conducted?
This trial is being conducted at Heidelberg, Germany.
Who is sponsoring the NCT05525325 clinical trial?
NCT05525325 is sponsored by University Hospital Heidelberg. The principal investigator is Silvia Schönenberger, MD at University Hospital Heidelberg. The trial plans to enroll 128 participants.
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.